Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 136

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 136
---
%7.01 %

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 15

Maturities of the Company’s operating lease liabilities are as follows (in thousands):YearAggregate MinimumPayments Due2025 (remaining nine months)$9,567 202612,769 202712,316 202811,168 202911,056 Thereafter6,326    Total future lease payments63,202    Less: imputed interest(10,119)   Total operating lease liabilities$53,083 

NOTE 8—GOODWILL AND INTANGIBLE ASSETS

GoodwillThe Company’s goodwill arose from the GQ Bio Acquisition in February 2025. The change in the carrying value of the Company’s goodwill is summarized as follows (in thousands):Carrying ValueBalance at December 31, 2023$163,243 Goodwill impairment(163,243)Balance at December 31, 2024— Goodwill arising from the GQ Bio Acquisition20,763 Foreign currency adjustments757 Balance at March 31, 2025$21,520 Intangible AssetsIntangible assets, net, consists of the in-process research and development, or IPR&D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition are summarized as follows (dollar amounts in thousands):March 31, 2025Gross Carrying ValueForeign currency adjustmentsAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $— $(213,254)$376,746 10 years, 5 monthsCustomer relationships90 — (54)36 10 yearsTotal finite-lived intangible assets, net590,090 — (213,308)376,782 Acquired IPR&D57,366 821 — 58,187      Total intangible assets, net$647,456 $821 $(213,308)$434,969 December 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $(198,934)$391,066 10 years, 5 monthsCustomer relationships90 (52)38 10 years